Well said, Drano. Once Phase 3 starts, the public
Post# of 72435
1. Actavis Receives Approval from the European Commission for XYDALBA™ (dalbavancin)
http://www.duratatherapeutics.com/news-media/...ission-for
2. The Medicines Company Receives European Commission Approval for Three Hospital Acute Care Products: KENGREXAL™ (cangrelor), ORBACTIV® (oritavancin) and RAPLIXA™ (sealant powder)
http://www.themedicinescompany.com/investors/...acute-care
3. CHMP Says Yes to Two Antibiotics for Skin Infections
http://www.medscape.com/viewarticle/838648
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
![Dont-give-up.jpg](https://styleshack.com/wp-content/uploads/2014/07/Dont-give-up.jpg)